Company Quick10K Filing
Juniper Pharmaceuticals
10-Q 2018-06-30 Filed 2018-08-09
10-Q 2018-03-31 Filed 2018-05-10
10-K 2017-12-31 Filed 2018-03-09
10-Q 2017-09-30 Filed 2017-11-02
10-Q 2017-06-30 Filed 2017-08-03
10-Q 2017-03-31 Filed 2017-05-04
10-K 2016-12-31 Filed 2017-03-07
10-Q 2016-06-30 Filed 2016-08-04
10-Q 2016-03-31 Filed 2016-05-04
10-K 2015-12-31 Filed 2016-03-10
10-Q 2015-09-30 Filed 2015-11-12
10-Q 2015-06-30 Filed 2015-08-04
10-Q 2015-03-31 Filed 2015-05-06
10-K 2014-12-31 Filed 2015-03-18
10-Q 2014-09-30 Filed 2014-10-31
10-Q 2014-06-30 Filed 2014-08-01
10-Q 2014-03-31 Filed 2014-05-02
10-K 2013-12-31 Filed 2014-03-05
10-Q 2013-09-30 Filed 2013-11-07
10-Q 2013-06-30 Filed 2013-08-07
10-Q 2013-03-31 Filed 2013-05-09
10-K 2012-12-31 Filed 2013-03-14
10-Q 2012-09-30 Filed 2012-11-08
10-Q 2012-06-30 Filed 2012-08-08
10-Q 2012-03-31 Filed 2012-05-04
10-K 2011-12-31 Filed 2012-03-12
10-Q 2011-09-30 Filed 2011-11-03
10-Q 2011-06-30 Filed 2011-08-04
10-Q 2011-03-31 Filed 2011-05-05
10-K 2010-12-31 Filed 2011-03-10
10-Q 2010-09-30 Filed 2010-11-04
10-Q 2010-06-30 Filed 2010-08-05
10-Q 2010-03-31 Filed 2010-05-06
10-K 2010-03-12 Filed 2010-03-12
8-K 2018-08-14 M&A, Shareholder Rights, Control, Officers, Amend Bylaw, Other Events, Exhibits
8-K 2018-08-09 Earnings, Exhibits
8-K 2018-07-02 Enter Agreement, Amend Bylaw, Other Events, Exhibits
8-K 2018-05-10 Earnings, Exhibits
8-K 2018-04-24 Enter Agreement, Regulation FD, Exhibits
8-K 2018-03-19 Officers
8-K 2018-03-08 Earnings, Exhibits
8-K 2018-01-31 Other Events, Exhibits
8-K 2018-01-07 Enter Agreement, Regulation FD, Exhibits

Juniper Pharmaceuticals Financials

JNP Metrics, Comps, Filings

Quarterly | Annual

Business

We are in the business of developing, manufacturing and selling to our marketing partners pharmaceutical products that utilize our proprietary bioadhesive drug delivery technologies to treat various medical conditions. Our focus is drug delivery across mucosal membranes, an area where we have a rich heritage and proven capabilities.

To date, we have developed and brought to market six products: five bioadhesive vaginal gel products that provide patient-friendly solutions for infertility, pregnancy support, amenorrhea, and other women's health conditions, and a bioadhesive buccal system for male hypogonadism. We have partnered or sold each of these products for commercialization in the various regions, as follows:

Copy History ProductPartner RegionPRESCRIPTION DRUGS CRINONE® 8% (progesterone gel) Merck Serono S.A. ("Merck Serono")ex-U.S. Actavis, Inc. ("Actavis", formerly Watson Pharmaceuticals, Inc.)U.S.CRINONE 4% (progesterone gel) ActavisU.S.STRIANT® (testosterone buccal system) Actient PharmaceuticalsU.S.The Urology CompanyU.K.Invaron PharmaceuticalsCanada OTC Products: Replens® Vaginal Moisturizer, RepHresh® Vaginal Gel, Advantage-S® and Advanced Formula Legatrin PM® Lil' Drug Store Products, Inc. ("Lil' Drug Store")U.S.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Equity

Income Statement ($MM Quarterly)

Revenue, G Profit, Net Income

Cash Flow ($MM Quarterly)

Ops, Inv, Fin

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Bay Banks of Virginia (BAYK) 104,674 3.9 0% 1,112,219 987,362 0 0 5,056 18,746 73,361
Epsilon Energy (EPSN) 103,584 0% 8.7 7% 95,010 19,649 11,983 0 6,665 9,734 84,837
Juniata Valley Financial (JUVF) 102,429 13.6 1% 667,107 593,321 0 0 5,568 9,850 134,126
F&M Bank (FMBM) 102,135 16.1 0% 813,237 722,344 0 0 2,734 8,653 139,285
Invesco CurrencyShares Australian Dollar Trust (FXA) 100,780 0% -56.1 1% 97,821 32 1,223 0 788 788 -44,220
Zoned Properties (ZDPY) 100,699 0% 277.2 0% 8,204 2,225 941 0 7 368 102,125
Virginia National Bankshares (VABK) 99,658 7.1 1% 660,790 585,236 0 0 5,258 10,047 71,803
Juniper Pharmaceuticals (JNP) 98,834 41% 49.7 -1% 67,768 19,275 55,610 22,712 -985 1,629 80,918
Hash Labs (HLAB) 98,593 -24.3 -2,247% 181 419 0 0 -4,067 -4,048 98,439
Nuvera Communications (NUVR) 98,504 0% 7.1 4% 164,114 84,747 48,592 0 6,727 21,163 151,275
ITUS (ITUS) 98,193 0% -9.7 -142% 6,843 1,044 250 0 -9,708 -9,689 93,796
Capital Properties (CPTP) 97,349 0% 30.3 23% 9,785 1,837 3,907 0 2,261 3,127 94,790
Processa Pharmaceuticals (PCSA) 96,996 -40.0 -24% 10,821 2,151 0 0 -2,583 -2,410 96,491
Addentax Group (ATXG) 96,315 14% -113.5 -15% 5,879 8,162 9,240 1,309 -855 -847 96,046
Eaco (EACO) 95,530 28% 6.2 10% 88,765 40,144 215,534 60,071 9,012 14,872 92,780
Cortland Bancorp (CLDB) 95,237 7.1 1% 700,621 626,468 0 0 5,378 10,511 74,729
ChoiceOne Financial Services (COFS) 94,691 0% 8.1 1% 663,589 578,963 3,629 0 5,973 9,668 78,117
Aerkomm (AKOM) 94,280 1% -11.7 -17% 51,277 3,924 1,600 13 -8,941 -7,810 91,529
Invuity (IVTY) 92,683 67% -2.9 -75% 48,729 46,397 40,834 27,211 -36,461 -31,788 93,415
First National (FXNC) 92,475 0% 5.0 1% 777,193 701,877 5,726 0 6,840 12,425 62,102

Balance Sheet ($'000)2011-06-302011-09-302011-12-312012-03-312012-06-302012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-30
Cash21,76111,32710,1147,5517,71710,18613,20413,77131,42118,81720,71512,24311,75716,39716,76216,30116,13017,44713,90113,47012,97514,97120,99421,75921,46422,10621,44620,68520,826
Accounts Receivable9,0753,1004,6952,8274,4844,8663,4233,5933,6746,8487,1977,2587,2095,2525,2894,8036,4667,8737,5387,9996,1545,2556,5734,5056,9006,5214,7348,73710,772
Inventory2,7823,3433,6364,8464,4393,7072,6272,2402,5841,9942,5832,4053,5502,8573,2013,3333,7793,1063,6233,2093,9374,8385,6215,6945,2125,8976,3266,3186,280
PP&E8808514,3552,3892,2062,0204,12783678712,72715,82816,74317,49817,14517,04616,60517,73517,92718,17218,39417,98918,65119,70220,62022,11523,06823,71025,06526,492
Assets35,64734,63536,08334,25335,11636,70036,93837,07140,44159,78160,09251,61353,24653,72252,20850,47054,23155,69951,37951,58948,99949,00957,57156,80960,02861,75561,22064,53967,768
Accounts Payable3,3002,9073,5263,3522,1822,1831,5051,4071,8042,5562,8053,1903,1241,1342,8732,5202,9973,3832,0043,8243,8314,7783,8932,7063,4614,6074,0385,0797,173
Long-Term Debt3,7303,9953,7193,7403,5033,5323,0833,2033,0293,1352,7532,5032,3702,4073,8673,9143,9042,4223,2322,909
Liabilities18,01512,50614,8527,6476,4237,9715,0223,8294,49818,18012,66511,89012,60910,50210,79010,20612,61513,47611,41211,81312,15917,68917,25117,36719,73221,84219,70813,51919,275
Stockholders' Equity17,03321,52920,63126,00728,09328,72931,36532,69235,39341,05046,87839,17340,08742,67040,86839,71441,06641,67339,41739,22636,29030,77039,77038,89240,29639,91341,51251,02048,493
Income Statement ($'000)2011-06-302011-09-302011-12-312012-03-312012-06-302012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-30
Revenue19,2444,9475,4413,8348,2316,6737,0916,3167,9787,1267,8077,2486,97911,4637,2598,32610,21311,4557,56412,10111,88511,55620,93011,24713,95612,98611,79015,52415,310
Cost of Revenue3,0023,1243,5302,0034,4663,1873,1332,8422,8313,2384,3404,2723,8695,1004,4484,8785,5706,4302,1856,3506,4675,7052,0686,5567,6507,7197,0369,0269,117
Gross Profit16,2421,8222,8471,8313,7653,4863,9593,4745,1473,8873,4672,9762,9886,3632,8113,4484,6435,0253,0285,7515,4185,85115,1594,6916,3065,2674,7546,4986,193
R&D508509417554204144-8602363511,3842,1321,5981,8341,7523,5502,3041,4421,3461,6482,2911,5759741,055
SG&A2,5301,9091,3432,5511,9231,9022,1942,4612,8781,6732,5172,8523,8852,6152,2002,8952,8442,5583,4103,7323,6233,3704,6004,8005,0143,7553,6754,5087,081
Tax2902053216-533331412175-110920533-6448-54405-45-1410300
Net Income18,3144,417-1,0174,9542,4803892,6311,2423,510-3,1545,9604293,7763,670-494-692-326953-2,069362-1,7462489,614-1,441-376-1,4101,167772-1,514
Cash Flow ($'000)2011-06-302011-09-302011-12-312012-03-312012-06-302012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-30
Cash Operating4,634-450-1,6142702,5963,0927082,2801,9282,1578845,071989-1761382,111-2,9643711513,1587,506-1386291,742-106-1,101
Cash Investing-15,037-747-976-69-121-55-6415,307-14,653-275-799-306-506-168-357-690-493-720-482-1,054-1,308-520-884-1,000-436-875
Cash Financing-8-8-8-8-35-29-7-7-4-71-8,562-70-52-6617-68-89-64-72-60-581,415-110-133-1331,189